Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2014 Nov;4(11):1299-309. doi: 10.1158/2159-8290.CD-14-0471. Epub 2014 Aug 19.

2.

Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.

Morrow CJ, Trapani F, Metcalf RL, Bertolini G, Hodgkinson CL, Khandelwal G, Kelly P, Galvin M, Carter L, Simpson KL, Williamson S, Wirth C, Simms N, Frankliln L, Frese KK, Rothwell DG, Nonaka D, Miller CJ, Brady G, Blackhall FH, Dive C.

Ann Oncol. 2016 Jun;27(6):1155-60. doi: 10.1093/annonc/mdw122. Epub 2016 Mar 24.

3.

Classification of circulating tumor cells by epithelial-mesenchymal transition markers.

Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, Yang D, Deng H, Yang N, Xu J.

PLoS One. 2015 Apr 24;10(4):e0123976. doi: 10.1371/journal.pone.0123976. eCollection 2015.

4.

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.

Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O.

BMC Cancer. 2012 May 16;12:178. doi: 10.1186/1471-2407-12-178.

5.

Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K.

J Neurosurg. 2015 Feb;122(2):317-23. doi: 10.3171/2014.10.JNS132159. Epub 2014 Nov 21.

PMID:
25415071
6.

Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.

Li TT, Liu H, Li FP, Hu YF, Mou TY, Lin T, Yu J, Zheng L, Li GX.

World J Gastroenterol. 2015 Dec 21;21(47):13259-67. doi: 10.3748/wjg.v21.i47.13259.

7.

Emerging circulating biomarkers in glioblastoma: promises and challenges.

Touat M, Duran-Peña A, Alentorn A, Lacroix L, Massard C, Idbaih A.

Expert Rev Mol Diagn. 2015;15(10):1311-23. doi: 10.1586/14737159.2015.1087315. Review.

8.

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Science. 2013 Feb 1;339(6119):580-4. doi: 10.1126/science.1228522.

9.

Enhanced detection and comprehensive in situ phenotypic characterization of circulating and disseminated heteroploid epithelial and glioma tumor cells.

Ge F, Zhang H, Wang DD, Li L, Lin PP.

Oncotarget. 2015 Sep 29;6(29):27049-64. doi: 10.18632/oncotarget.4819.

10.

Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.

Kang W, Kim SH, Cho HJ, Jin J, Lee J, Joo KM, Nam DH.

Oncotarget. 2015 Sep 29;6(29):27239-51. doi: 10.18632/oncotarget.4835.

11.

Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.

Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R.

Cell Adh Migr. 2016 Jul 3;10(4):360-7. doi: 10.1080/19336918.2016.1155019. Epub 2016 Feb 26.

12.
13.

Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.

Mego M, Cierna Z, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Sieberova G, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J.

BMC Cancer. 2015 Jul 22;15:533. doi: 10.1186/s12885-015-1548-7.

14.

Differential expression of 2',3'-cyclic-nucleotide 3'-phosphodiesterase and neural lineage markers correlate with glioblastoma xenograft infiltration and patient survival.

Zorniak M, Clark PA, Leeper HE, Tipping MD, Francis DM, Kozak KR, Salamat MS, Kuo JS.

Clin Cancer Res. 2012 Jul 1;18(13):3628-36. doi: 10.1158/1078-0432.CCR-12-0339. Epub 2012 May 15.

15.

Hematogenous dissemination of glioblastoma multiforme.

Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K, Riethdorf S.

Sci Transl Med. 2014 Jul 30;6(247):247ra101. doi: 10.1126/scitranslmed.3009095.

16.

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.

Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S.

BMC Cancer. 2014 Sep 3;14:651. doi: 10.1186/1471-2407-14-651.

17.

Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.

Cierna Z, Mego M, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Cingelova S, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J.

BMC Cancer. 2014 Jun 28;14:472. doi: 10.1186/1471-2407-14-472.

18.

Clinical and biological significance of circulating tumor cells in cancer.

Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K.

Mol Oncol. 2016 Mar;10(3):408-17. doi: 10.1016/j.molonc.2016.01.010. Epub 2016 Feb 10. Review.

19.

TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion.

Joseph JV, Conroy S, Tomar T, Eggens-Meijer E, Bhat K, Copray S, Walenkamp AM, Boddeke E, Balasubramanyian V, Wagemakers M, den Dunnen WF, Kruyt FA.

Cell Death Dis. 2014 Oct 2;5:e1443. doi: 10.1038/cddis.2014.395.

20.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S.

Breast Cancer Res. 2011 Jun 10;13(3):R59. doi: 10.1186/bcr2896.

Supplemental Content

Support Center